Quantum BioPharma is trading 5% down at $3.27 amid broader risk-off market pressure, with the Nasdaq Composite down 0.65% and elevated Treasury yields weighing on growth-oriented stocks.
- No new company-specific catalyst was identified on August 24, 2026.
- Recent disclosures were generally constructive, including lower second-quarter expenses and FDA clearance to advance Lucid-MS into Phase 2 clinical development.